Trials / Completed
CompletedNCT02591784
Nimotuzumab in Combination With Radiotherapy for Esophageal Cancer
The Phase II of Nimotuzumab in Combination With Radiotherapy for Esophageal Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 42 (actual)
- Sponsor
- Biotech Pharmaceutical Co., Ltd. · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Nimotuzumab (hR3) is an IgG1 humanized monoclonal antibody that recognized an epitope located in the extra cellular domain of the human epidermal growth factor receptor (EGFR). Clinical efficacy has been shown in adult with head and neck cancer. The phase II study assessed the efficacy and safety of the combination of Nimotuzumab administered concomitantly with radiotherapy in patients with esophageal cancer tumours.
Detailed description
Clinical efficacy has been shown in adult with head and neck cancer. The phase II study assessed the efficacy and safety of the combination of Nimotuzumab administered concomitantly with radiotherapy in patients with esophageal cancer tumours.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nimotuzumab | the nimotuzumab treatment; 200mg/w,weekly,5-6 weeks. |
| RADIATION | Radiotherapy | the Radiotherapy treatment;95%PTV A dose of 50-60Gy will be administered in 25-30 fractions ( 2 Gy /fraction) |
Timeline
- Start date
- 2008-11-01
- Primary completion
- 2011-12-01
- Completion
- 2011-12-01
- First posted
- 2015-10-30
- Last updated
- 2022-03-17
Locations
5 sites across 1 country: China
Source: ClinicalTrials.gov record NCT02591784. Inclusion in this directory is not an endorsement.